Akebia Therapeutics, Inc. (AKBA) Stock Grade

About Akebia Therapeutics, Inc.'s fundamentals

Akebia Therapeutics is a biotechnology company with a market capitalization of $414.0 million that reported strong revenue growth of 47.5% year-over-year, indicating expanding commercial operations. Despite this growth, the company posted a net loss with a negative net margin of -2.3%, though it generated positive free cash flow in its latest period, suggesting operational efficiency despite accounting losses. The company does not pay dividends and lacks traditional profitability metrics like P/E ratio and return on equity due to its loss-making status.